Why Vertex Pharmaceuticals Stock Is Sinking Today
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.
Vertex reported Q1 revenue of $2.77 billion, up 3% year over year. It posted adjusted earnings of $1.24 billion, or $4.76 per share, up from $1.05 billion, or $4.06 per share, in the prior-year period. However, both top- and bottom-line numbers missed the consensus Wall Street estimates.
In addition, Vertex revealed that it has temporarily paused the multiple ascending dose portion of its phase 1/2 study evaluating experimental messenger RNA (mRNA) therapy VX-522 in treating cystic fibrosis (CF). The company didn't provide any details, stating only that there was a "tolerability issue."
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Starkes Kaufinteresse bei Vertex Pharmaceuticals Inc., mit einer großen Anzahl an Buy- und wenigen Sell-Einschätzungen.
Mit einem Kursziel von 473 € für Vertex Pharmaceuticals Inc. könnte eine leichte Steigerung gegenüber dem aktuellen Kurs von 455.65 € erreicht werden.
